Engineered botulinum neurotoxin B with improved efficacy for targeting human receptors

Liang Tao; Lisheng Peng; Ronnie P.-A. Berntsson; Sai Man Liu; SunHyun Park; Feifan Yu; Christopher Boone; Shilpa Palan; Matthew Beard; Pierre-Etienne Chabrier; Pål Stenmark; Johannes Krupp; Min Dong

doi:10.1038/s41467-017-00064-y

Nature Communications (Jul 2017)

Engineered botulinum neurotoxin B with improved efficacy for targeting human receptors

Liang Tao,
Lisheng Peng,
Ronnie P.-A. Berntsson,
Sai Man Liu,
SunHyun Park,
Feifan Yu,
Christopher Boone,
Shilpa Palan,
Matthew Beard,
Pierre-Etienne Chabrier,
Pål Stenmark,
Johannes Krupp,
Min Dong

Affiliations

Liang Tao: Department of Urology, Boston Children’s Hospital, Department of Microbiology and Immunobiology, Department of Surgery, Harvard Medical School
Lisheng Peng: Department of Urology, Boston Children’s Hospital, Department of Microbiology and Immunobiology, Department of Surgery, Harvard Medical School
Ronnie P.-A. Berntsson: Department of Biochemistry and Biophysics, Stockholm University
Sai Man Liu: IPSEN Bioinnovation
SunHyun Park: Department of Urology, Boston Children’s Hospital, Department of Microbiology and Immunobiology, Department of Surgery, Harvard Medical School
Feifan Yu: Department of Urology, Boston Children’s Hospital, Department of Microbiology and Immunobiology, Department of Surgery, Harvard Medical School
Christopher Boone: Department of Urology, Boston Children’s Hospital, Department of Microbiology and Immunobiology, Department of Surgery, Harvard Medical School
Shilpa Palan: IPSEN Bioinnovation
Matthew Beard: IPSEN Bioinnovation
Pierre-Etienne Chabrier: IPSEN Innovation
Pål Stenmark: Department of Biochemistry and Biophysics, Stockholm University
Johannes Krupp: IPSEN Bioinnovation
Min Dong: Department of Urology, Boston Children’s Hospital, Department of Microbiology and Immunobiology, Department of Surgery, Harvard Medical School

DOI: https://doi.org/10.1038/s41467-017-00064-y
Journal volume & issue: Vol. 8, no. 1
pp. 1 – 10

Abstract

Read online

Humans are less sensitive to the therapeutic effects of botulinum neurotoxin B (BoNT/B) than the animal models it is tested on due to differences between the human and the mouse receptors. Here, the authors engineer BoNT/B to improve its affinity to human receptors and enhance its therapeutic efficacy.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal